Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T09:11:39.542Z Has data issue: false hasContentIssue false
  • English
  • Français

The Aftercare of the Patient with the Neuroleptic Malignant Syndrome

Published online by Cambridge University Press:  29 January 2018

Dov Aizenberg ,
Arieh Shalev  and
Hanan Munitz
Dov Aizenberg
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tiqva 49100, Israel
Arieh Shalev
Affiliation:
Geha Psychiatric Hospital
Hanan Munitz
Affiliation:
Geha Psychiatric Hospital
Get access Rights & Permissions [Opens in a new window]

Summary

The neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic drugs, made up of hyperthermia, muscular rigidity, disturbance of level of consciousness and autonomic dysfunction. It is potentially lethal and should be kept in mind whilst using anti-psychotic drugs; as most patients treated by them require further anti-psychotic treatment, the clinician faces the problem of treating those patients after a NMS episode, yet reports in the literature have generally neglected the problem of late management. A patient suffering from a psychosis and NMS is presented, and a rationale for management offered.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 146 , Issue 3 , March 1985 , pp. 317 - 318
Copyright
Copyright © 1985 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allan, R. N. & White, H. C. (1972) Side effects of parenteral long-acting phenothiazines. British Medical Journal, 1, 221.Google Scholar
Bernstein, R. A. (1979) Malignant neuroleptic syndrome: an atypical case. Psychosomatics, 20, 840–846.Google Scholar
Caroff, S. N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79–83.Google Scholar
Caroff, S., Rosenberg, H. & Gerber, J. C. (1983) Neuroleptic malignant syndrome and malignant hyperthermia. Lancet, 333, 224.Google Scholar
Coons, D. J., Hillman, F. J. & Marshall, R. W. (1982) Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. American Journal of Psychiatry, 139, 944–945.Google Scholar
Cope, R. V. & Gregg, E. M. (1983) The neuroleptic malignant syndrome. British Medical Journal, 286, 1938.Google Scholar
Dillon, J. B. (1972) Parenteral long-acting phenothiazines. British Medical Journal, i, 807.Google Scholar
Goekoop, J. G. & Carbaat, P. A.Th. (1982) Treatment of neuroleptic malignant syndrome with dantrolene. Lancet, 332, 49–50.Google Scholar
Henderson, V. W. & Wooten, G. F. (1981) Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology (NY), 31, 132–137.Google Scholar
Itoh, H., Oktsuk, A.N., Ogita, K., Yagi, G., Miura, S. & Koga, (1977) Malignant neuroleptic syndrome—its present status in Japan and clinical problems. Folia Psychiatrica et Neurologica Japonica, 31, 565–567.Google Scholar
Jesse, S. S., Anderson, G. F. (1983) ETC in the neuroleptic malignant syndrome: case report. Journal of Clinical Psychiatry, 44, 186–188.Google Scholar
Meltzer, H. Y. (1973) Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia (Berlin). 29, 337–346.Google Scholar
Powers, P., Douglas, T. S. & Waziri, R. (1976) Hyperpyrexia in catatonic states. The Journal of Nenous and Mental Disease, 37, 359–361.Google Scholar
Regestein, Q. R., Alpert, J. S. & Reich, P. (1979) Sudden catatonic stupor with disastrous outcome. Journal of American Medical Association, 238, 618–620.Google Scholar
Smego, R. A. & Durack, D. T. (1982) The neuroleptic malignant syndrome. Archives of Internal Medicine, 142, 1183–1185.Google Scholar
Szabadi, E. (1984) Neuroleptic malignant syndrome. British Medical Journal, 288, 1399–1400.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.